Truist Financial Forecasts Strong Price Appreciation for Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price boosted by research analysts at Truist Financial from $33.00 to $38.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would indicate a potential upside of 55.48% from the stock’s previous close.

Other research analysts have also recently issued reports about the company. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research note on Friday, January 2nd. TD Cowen reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, January 14th. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, November 18th. Oppenheimer lifted their price target on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.50.

Centessa Pharmaceuticals Stock Down 3.2%

Shares of CNTA stock traded down $0.80 during trading on Thursday, reaching $24.44. The company’s stock had a trading volume of 152,536 shares, compared to its average volume of 1,666,589. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $30.58. The stock’s 50-day moving average price is $25.68 and its 200 day moving average price is $22.28. The company has a market capitalization of $3.29 billion, a price-to-earnings ratio of -13.36 and a beta of 1.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, research analysts anticipate that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Insiders Place Their Bets

In other Centessa Pharmaceuticals news, insider Mario Alberto Accardi sold 10,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the transaction, the insider owned 178,801 shares in the company, valued at $5,364,030. This represents a 5.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CTO Tia L. Bush sold 40,000 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $26.00, for a total value of $1,040,000.00. Following the completion of the sale, the chief technology officer directly owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.09% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Institutional investors have recently modified their holdings of the business. TD Waterhouse Canada Inc. acquired a new stake in Centessa Pharmaceuticals during the 4th quarter worth $25,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock valued at $117,000 after buying an additional 979 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth about $218,000. DNB Asset Management AS purchased a new position in shares of Centessa Pharmaceuticals during the third quarter worth about $218,000. Finally, China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 4.8% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 19,181 shares of the company’s stock valued at $252,000 after acquiring an additional 870 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.